Title: Achieving Minimal Residual Disease (MRD) Negativity during the Disease Course in relapsed/refractory Multiple Myeloma (RRMM): Implications for Treatment and Transplant Strategies | Synapse
March 3, 2026
Title: Achieving Minimal Residual Disease (MRD) Negativity during the Disease Course in relapsed/refractory Multiple Myeloma (RRMM): Implications for Treatment and Transplant Strategies
Puntos clave
MRD negativity is crucial for better outcomes in relapsed/refractory multiple myeloma, suggesting improved treatment strategies.
Key evidence shows that achieving MRD negativity significantly correlates with prolonged survival and decreased relapse rates.
Analysis included various treatment approaches to achieve MRD negativity, utilizing patient data over several stages of disease management.
Highlights the need for tailored treatment and transplant strategies in patients, emphasizing potential improvements in survival rates.